Landmark $2M detransitioner lawsuit and new guidelines raise concerns over adolescent gender-transition surgeries in the US ...

New research suggests that Epstein-Barr virus may actively provoke the immune system in people with multiple sclerosis. Scientists found large buildups of virus-targeting immune cells in the nervous ...

Since taking over as CEO of the Cambridge biotech more than three years ago, Chris Viehbacher has cut hundreds of jobs and reduced expenses, in part by removing drugs from its research pipeline.

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

Advancements in MS include promising therapies like BTK inhibitors and myelin repair, evolving biomarkers, and a focus on cognition, signaling a promising future in precision medicine.

Immunic presents additional phase 2 CALLIPER trial data for vidofludimus calcium in patients with progressive MS at the ACTRIMS Forum 2026: New York Friday, February 6, 2026, 16:0 ...

A Queensland not-for-profit mental health clinic that delivers novel therapies such as ketamine and psilocybin is expanding ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

The results reinforce the need for individualized, biology-driven therapeutic decisions in patients with MS. SAN DIEGO – ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

In a legal first, a jury in New York awarded $2 million to a patient who said that doctors had deviated from accepted medical standards.